Androgen deprivation therapy use with post‐prostatectomy radiotherapy in the Prostate Cancer Outcomes Registry Victoria

The aim of this study is to evaluate the use of androgen deprivation therapy ( ADT ) with post‐prostatectomy radiotherapy ( PPRT ) in a population‐based cohort of Australian men. Methods This is a prospective cohort of men with localised prostate cancer captured in the Prostate Cancer Outcomes Registry Victoria ( PCOR ‐Vic), who received PPRT between January 2010 and December 2015. The primary outcome was ADT use with PPRT . Multivariate logistic regressions were used to identify patient, tumour and institutional factors influencing ADT use. Results 485 men were included in this study – 115 (24%) had pT 2 disease, 231 (48%) pT 3a, 134 (28%) pT 3b and 5 (1%) pT 4. Eighteen (4%) men had ISUP grade 1 disease, 139 (29%) ISUP grade 2, 170 (35%) ISUP grade 3 and 158 (33%) ISUP grade 4/5, while 267 (64%) men had positive surgical margins. Median time from prostatectomy to PPRT was 8.1 months ( IQR  = 5.3–13.9). Sixty‐six (14%) patients had ADT with PPRT . In multivariate analyses, men who had increased age ( OR  = 1.06; 95% CI  = 1.01–1.11), seminal vesicle involvement ( OR  = 3.81; 95% CI  = 1.63–8.91) and underwent treatment in regional centres ( OR  = 2.17; 95% CI  = 1.08–4.33) were more likely to have ADT with PPRT. Conclusion We reported that 14% of men treated with PPRT received ADT in a population‐based cohort of Australian men, which was less than half of the proportion of ADT use with PPRT in the US . It will be of interest to evaluate the uptake of ADT with PPRT in the coming years following recent publications of level 1 evidence confirming overall survival benefits of ADT with PPRT .